H.C. Wainwright Reiterates Buy Rating on Achieve Life Sciences (ACHV)

H.C. Wainwright analyst Brandon Folkes reiterated a Buy rating and $12.00 price target on Achieve Life Sciences (NASDAQ: ACHV).

The analyst commented: "ACHV’s 2Q26 results reinforce our view that the key risks have shifted away from financing and cytisinicline’s clinical approvability and toward execution of the planned 4Q26 NDA resubmission and subsequent commercial launch. The most important financial metric this quarter, in our view, is the $187.3M of cash, cash equivalents and marketable securities at June 30. With the balance sheet now strengthened, the FDA having identified no clinical efficacy or clinical safety deficiencies in its June CRL, and ACHV continuing to target a 4Q26 resubmission with Adare (private) followed by potential approval and launch in 1H27, we believe the investment focus should increasingly shift toward commercial execution and the size of the smoking cessation opportunity. We reiterate our Buy rating and $12 price target. The CRL is a timing and execution issue rather than a clinical or financing issue; with $187M in cash and up to another $174M available from approval-linked warrants, ACHV appears well capitalized to execute through resubmission and launch."

For an analyst ratings summary and ratings history on Achieve Life Sciences click here. For more ratings news on Achieve Life Sciences click here.

Shares of Achieve Life Sciences closed at $6.77 yesterday.

You May Also Be Interested In

• Londian Wason New Energy Tech opens at $26, above IPO price of $22
• Truist Securities Reiterates Buy Rating on ARAMARK Holdings (ARMK)
• Lumentum (LITE) PT Raised to $820 at TD Cowen